DNA methyltransferases (DNMTs) are epigenetic regulators targeted to the treatment of hematological malignancies.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ Mutations in the DNA methyltransferase *DNMT3A* and high expression of its paralogue *DNMT3B* have been associated with inferior outcome in acute myeloid leukemia (AML) and other hematological malignancies.^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8]^ Using a publicly available gene expression data set,^[@bib9]^ we studied whether DNMT3B expression correlates with outcome in genetically well-defined AML subgroups. We first validated the expression data from the microarray by quantitative PCR, using 39 patient samples ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}). *DNMT3B* micro-array analyses showed that the expression was not normally distributed among AML patients; in the quartile with highest expression, a larger variation in expression was observed compared to the three quartiles with relatively lower expression ([Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}). The median *DNMT3B* expression in AML samples was significantly lower compared with that observed in normal bone marrow (NBM)-derived CD34^+^ cells (*P*\<0.0001), while it was higher compared to NBM cells, but the latter difference was not statistically significant ([Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}). Subsequently, we investigated the correlation between *DNMT3B* expression and overall survival (OS) and event-free survival (EFS). In univariate Cox regression analyses, continuous *DNMT3B* expression was significantly associated with poor survival (*P*\<0.001 for both OS and EFS, data not shown). To visualize the prognostic impact, we performed Kaplan--Meier analyses on the four quartiles based on expression levels. The quartile including the patients with the highest *DNMT3B* expression, exhibiting the largest variation in expression, showed a significantly reduced OS and EFS compared to the other quartiles ([Supplementary Fig. S2](#sup1){ref-type="supplementary-material"}). As the survival between the lower three quartiles did not differ significantly, we grouped these patients together as having lower *DNMT3B* expression, whereas the remaining patients were ranked as having higher *DNMT3B* expression. Using these criteria, the 5-year OS and EFS were 17.2%±3.3% and 13.6%±3.0% for patients with higher *DNMT3B* expression compared to 43.8%±2.5% and 34.4%±2.4% for patients with lower *DNMT3B* levels (*P*\<0.001, [Figure 1a](#fig1){ref-type="fig"}). We next performed a multivariate Cox regression analysis including known prognostic factors (including age \>60 years; white blood cell counts \>100 × 10^9^/l; transplantation status; karyotypes t(8;21), t(15;17) and inv(16); nucleophosmin 1 (*NPM1*), *FLT3-ITD*, *DNMT3A* and double *CEBPA* mutations, and ecotropic viral integration site 1 (*EVI1*) overexpression), which revealed that higher *DNMT3B* expression carried an independent prognostic risk for both OS and EFS (hazard ratio (HR): 1.768, 95% confidence interval (CI): 1.384--2.260; *P*\<0.001 and HR: 1.706, 95% CI: 1.342--2.168; *P*\<0.001, respectively, [Table 1](#tbl1){ref-type="table"}), in line with a recently published study.^[@bib7]^ In fact, higher *DNMT3B* expression showed a higher hazard ratio for OS than that of well-known adverse prognostic factors such as internal tandem duplications of the fms-related tyrosine kinase 3 (*FLT3-ITD*, HR: 1.675, 95% CI: 1.287--2.179; *P*\<0.001) and overexpression of the *EVI1* gene (HR: 1.430, 95% CI: 0.999--2.047; *P*=0.051).

We then studied the association of higher *DNMT3B* expression with specific AML subcategories. Higher *DNMT3B* expression was under-represented in FAB-M4 and mutually exclusive with the favorable karyotypes t(8;21) and inv(16), as shown in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. In contrast, higher *DNMT3B* expression was over-represented in the FAB-M1 subcategory ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}), and predicted poor OS and a trend toward poor EFS in this group (data not shown). A significant association between higher *DNMT3B* expression and *EVI1* overexpression and *IDH2* mutations was also observed ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}), but not with *IDH1* mutations. *DNMT3B* expression did not predict clinical outcome in these subgroups (data not shown). We also observed that higher *DNMT3B* expression was associated with a normal karyotype (NK, *P*=0.017), and strongly associated with mutations in *NPM1* (*NPM1*^*+*^, *P*\<0.001) and *FLT3-ITD* (*FLT3-ITD*^*+*^, *P*\<0.001, [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Patients with NK can be classified based on *NPM1* and *FLT3-ITD* mutational status. *NPM1* mutations, particularly in the absence of *FLT3-ITD*, display a favorable disease outcome, whereas the presence of a *FLT3-ITD* mutation is generally considered as an adverse prognostic factor.^[@bib10]^ Remarkably, among patients with NK, higher *DNMT3B* expression did not significantly associate with *NPM1*^−^/*FLT3-ITD*^−^ status and was under-represented in the *NPM1*^*+*^*/FLT3-ITD*^−^ and *NPM1*^−^/*FLT3-ITD*^+^ groups, but was significantly over-represented in the *NPM1*^*+*^*/FLT3-ITD*^*+*^ group ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Within the latter group, patients with higher *DNMT3B* expression showed a significantly worse outcome than patients with lower *DNMT3B* expression ([Figure 1b](#fig1){ref-type="fig"}). The 5-year OS and EFS of patients with higher *DNMT3B* expression were 16.7%±6.2% (*P*=0.001) and 16.7%±6.2% (*P*=0.005) compared to 47.6%±8.8% and 39.0%±8.6% in patients with lower *DNMT3B* expression. The survival of patients with co-occurring *NPM1* and *FLT3-ITD* mutations is negatively influenced by high *FLT3-ITD* allelic burden.^[@bib11],\ [@bib12],\ [@bib13]^ Higher *DNMT3B* expression was observed in both patients with low and those with high *FLT3-ITD* allelic burden ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). We next analyzed whether *DNMT3B* expression had an effect on survival among these subgroups. Higher *DNMT3B* expression did not exhibit a significant effect on OS and EFS among patients with low *FLT3-ITD* allelic burden (data not shown). However, patients with higher *DNMT3B* expression showed an extremely poor OS and EFS (5-year OS: 0.0%±0.0%, 5-year EFS: 0.0%±0.0%, *P*\<0.001), compared to patients with lower *DNMT3B* expression (5-year OS: 38.9%±12.9%, 5-year EFS: 32.0%±12.4%) within the subgroup with high *FLT3-ITD* allelic burden ([Figure 1c](#fig1){ref-type="fig"}). In multivariate analysis, higher *DNMT3B* expression showed an independent prognostic value for OS and EFS, with a high hazard ratio both in the *NPM1*^+^/*FLT3-ITD*^+^ subgroup (HR: 4.850, 95% CI: 1.980--11.880) and among those patients with high *FLT3-ITD* allelic burden, indicating that the latter subgroup can be separated into two groups, one with an intermediate and the other with an extremely poor survival, based on *DNMT3B* expression ([Table 1](#tbl1){ref-type="table"}).

In conclusion, these data show that higher *DNMT3B* expression is a strong independent predictive factor for poor disease outcome in AML in general, and especially among *NPM1*^*+*^*/FLT3-ITD*^*+*^ patients with normal karyotype. Drugs that inhibit DNA methylation are tested for clinical efficacy in AML.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ Because *DNMT3B* catalyzes DNA methylation, its expression level may affect the therapeutic sensitivity to these drugs. Thus, it will be interesting to investigate whether *DNMT3B* expression predicts therapy responses to treatments affecting DNA methylation.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on Blood Cancer Journal website (http://www.nature.com/bcj)
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###### 

Click here for additional data file.

![Higher *DNMT3B* expression correlates with inferior OS and EFS in AML. (**a**) Kaplan--Meier plots for OS and EFS showed that higher *DNMT3B* expression correlated significantly with a poor OS and EFS among AML patients (5-year OS: 17.2%±3.3% vs 43.8%±2.5% and 5-year EFS: 13.6%±3.0% vs 34.4%±2.4% for patients with higher and lower *DNMT3B* expression, respectively). (**b**) Higher *DNMT3B* expression predicted a very poor OS and EFS among patients with normal karyotype carrying *NPM1* and *FLT3-ITD* mutations compared to patients with lower *DNMT3B* expression (5-year OS: 16.7±6.2% vs 47.6±8.8%, *P*=0.001 and 5-year EFS: 16.7±6.2% vs 39.0±8.6%, *P*=0.005 for patients with higher and lower *DNMT3B* expression, respectively). (**c**) Within the group of patients with normal karyotype that carries *NPM1* mutations with high *FLT3-ITD* allelic burden, higher *DNMT3B* expression correlated with an extremely poor OS and EFS compared to patients with lower *DNMT3B* expression (5-year OS: 0%±0.0% vs 38.9%±12.9%, *P*\<0.001 and 5-year EFS: 0%±0.0% vs 32.0%±12.4%, *P*\<0.001 for patients with higher and lower *DNMT3B* expression, respectively). *P* values were determined with the log-rank test. In agreement with de Jonge *et al.,*^[@bib13]^ high *FLT3-ITD* allelic burden was defined as an allelic *FLT3-ITD*/*FLT3* ratio \>1.](bcj201451f1){#fig1}

###### Data proving that *DNMT3B* expression is a prognostic factor in AML, particularly in *NPM1* ^+^/ *FLT3-ITD* ^+^ patients with normal karyotype

                                                         *OS*                    *EFS*                                 
  ------------------------------------------------------ ----------------------- ------------- ----------------------- -------------
  *AML*                                                                                                                
   Higher *DNMT3B* exp.                                  1.768 (1.384--2.260)    **\<0.001**   1.706 (1.342--2.168)    **\<0.001**
   Age\>60 years                                         1.523 (1.111--2.087)    **0.009**     1.339 (0.985--1.821)    0.063
   WBC count\>100 × 10^9^/l                              1.448 (1.098--1.909)    **0.009**     1.531 (1.173--1.997)    **0.002**
   *FLT3-ITD* mutations                                  1.675 (1.287--2.179)    **\<0.001**   1.649 (1.274--2.136)    **\<0.001**
   *NPM1* mutations                                      0.397 (0.291--0.541)    **\<0.001**   0.381 (0.280--0.518)    **\<0.001**
   Favorable karyotype                                   0.388 (0.266--0.565)    **\<0.001**   0.457 (0.323--0.646)    **\<0.001**
   *CEBPA* double mutation                               0.338 (0.177--0.645)    **0.001**     0.361 (0.199--0.653)    **0.001**
   *DNMT3A* mutations                                    1.631 (1.204--2.210)    **0.002**     1.531 (1.136--2.063)    **0.005**
   *EVI1* overexpression                                 1.430 (0.999--2.047)    0.051         1.711 (1.208--2.423)    **0.002**
   Transplantation status                                0.700 (0.610--0.806)    **\<0.001**   0.758 (0.665--0.865)    **\<0.001**
                                                                                                                        
  *Normal karyotype*                                                                                                   
   *NPM1*^+^/*FLT3-ITD*^+^                                                                                             
    Higher *DNMT3B* expression                           3.090 (1.623--5.883)    **0.001**     2.414 (1.309--4.451)    **0.005**
    Age\>60 years                                        2.703 (1.134--6.438)    **0.025**     1.951 (0.831--4.583     0.125
    WBC count\>100 × 10^9^/l                             2.365 (1.270--4.404)    **0.007**     1.763 (0.958--3.246)    0.069
    High *FLT3-ITD* AB                                   3.791 (1.971--7.294)    **\<0.001**   3.130 (1.685--5.813)    **\<0.001**
   *NPM1*^*+*^*/FLT3-ITD*^*+*^ *with high FLT3-ITD AB*                                                                 
    Higher *DNMT3B* expression                           4.850 (1.980--11.880)   **0.001**     4.428 (1.824--10.749)   **0.001**
    Age\>60 years                                        2.007 (0.660--6.101)    0.219         1.478 (0.489--4.464)    0.489
    WBC count\>100 × 10^9^/l                             1.356 (0.634--2.901)    0.433         0.954 (0.446--2.043)    0.904

Abbreviations: AB, allelic burden; 95% CI, 95% confidence interval; EFS, event-free survival; HR, hazard ratio; OS, overall survival; WBC, white blood cell.

Multivariate Cox regression model for probability of OS and EFS. Favorable karyotype includes inv(16), t(8;21) and t(15;17). Transplantation status includes no transplantation, autologous transplantation or allogeneic transplantation. Age and WBC count are dichotomized. *DNMT3B* expression is dichotomized in multivariate analysis. *P*-values (bold) indicate whether differences are significant at the level of 0.05.

[^1]: These authors contributed equally to this work.

[^2]: Current address: The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G1X5, Canada.
